Neuronostics announces new user group to help develop its products

18th December 2019 Neuronostics are excited to announce plans to establish a user-group to help shape its products and offerings.  We are delighted to announce the first member of the group is Simon… [Read More]

Dr. Woldman presents to Birmingham Epilepsy Research Network

Wessel Woldman (our Scientific Director) delivered the opening lecture at the Birmingham Epilepsy Research Network meeting on Monday November 25th. The annual event, now in its 10th year, brings together clinicians, neurophysiologists,… [Read More]

Neuronostics announces Microsoft collaboration

Neuronostics Ltd, today announces that it has been selected by Microsoft for a new programme designed to help startups get off the ground. Microsoft for Startups will provide up to $500 million worth of… [Read More]

Epilepsy diagnostic specialist Neuronostics Ltd, appoints Dr. Wes Woldman as Scientific Director.

Neuronostics, the developer of #BioEP, the revolutionary epilepsy assessment tool, announces the appointment of Dr. Wessel (Wes) Woldman as Scientific Director.  Dr. Woldman, will lead and manage application research and development of… [Read More]

Neuronostics announces first new recruit to its senior management team

Neuronostics Ltd, developer of the revolutionary seizure susceptibility assessment technology called #BioEP, announces the appointment of Ross Parkman as Technical & Operations Director.  Mr Parkman, who previously 15 years at IT solutions… [Read More]

Neuronostics secures funding from Innovate UK and University of Exeter to accelerate development of #BioEP

Neuronostics Ltd, announces that in conjunction with the University of Exeter, it has been awarded £504,000 grant funding to accelerate the development of its potentially revolutionary seizure susceptibility technology called #BioEP. The… [Read More]